Brief: Mustang Bio Says Interim Chief Financial Officer Eliot Lurier Passed Away Unexpectedly
U.S. RESEARCH ROUNDUP-Beauty Health, Design Therapeutics, Energizer Holdings
Fortress Biotech shares plunge after highly dilutive offering
Brief: Mustang Bio Announces FDA Acceptance Of IND Application For MB-109
U.S. STOCKS ON THE MOVE-Nu Holdings, United States Steel, Mallinckrodt
U.S. STOCKS ON THE MOVE-Chevron, Coherent, HF Sinclair
Mustang Bio rises on initial data from early-to-mid-stage trial of cell therapy
Brief: Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating Mb-106 Car-T Cell Therapy
Mustang Bio Inc reports results for the quarter ended in June - Earnings Summary
Mustang Bio Inc expected to post a loss of $1.81 a share - Earnings Preview
Brief: Mustang Bio Announces Amendment And Closing Of Partnership With uBriGene Biosciences
Brief: Mustang Bio Terminates Exclusive License Agreement With Regents Of University Of California
Brief: Mustang Bio Announces Final Results From Follicular Lymphoma Cohort Of Single-Institution Phase 1/2 Clinical Trial Of MB-106
Brief: Mustang Bio - MB-106 Continues To Demonstrate Favorable Safety, Efficacy Profile
Brief: Mustang Bio Announces Strategic Manufacturing Partnership And Portfolio Updates
Brief: Mustang Bio Inc - QTRLY Loss Per Share $2.06
Mustang Bio Inc expected to post a loss of $3.01 a share - Earnings Preview
Brief: Mustang Bio Terminates Loan & Security Agreement By Payment Of $30.7 Million
Mustang Bio Inc reports results for the quarter ended in December - Earnings Summary